88 related articles for article (PubMed ID: 23131302)
1. [The mouse as preclinical models of lung cancer].
Francoz S; Mathiaux J; Dubus P
Bull Cancer; 2012 Nov; 99(11):1017-27. PubMed ID: 23131302
[TBL] [Abstract][Full Text] [Related]
2. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
3. Rare mutations in non-small-cell lung cancer.
D'Arcangelo M; D'Incecco A; Cappuzzo F
Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
[TBL] [Abstract][Full Text] [Related]
4. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
Chan SK; Gullick WJ; Hill ME
Eur J Cancer; 2006 Jan; 42(1):17-23. PubMed ID: 16364841
[TBL] [Abstract][Full Text] [Related]
6. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
[TBL] [Abstract][Full Text] [Related]
7. New driver mutations in non-small-cell lung cancer.
Pao W; Girard N
Lancet Oncol; 2011 Feb; 12(2):175-80. PubMed ID: 21277552
[TBL] [Abstract][Full Text] [Related]
8. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.
Benesova L; Minarik M; Jancarikova D; Belsanova B; Pesek M
Anticancer Res; 2010 May; 30(5):1667-71. PubMed ID: 20592359
[TBL] [Abstract][Full Text] [Related]
9. New targets in advanced NSCLC: EML4-ALK.
Crystal AS; Shaw AT
Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
[TBL] [Abstract][Full Text] [Related]
10. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
11. Mouse models of human non-small-cell lung cancer: raising the bar.
Kim CF; Jackson EL; Kirsch DG; Grimm J; Shaw AT; Lane K; Kissil J; Olive KP; Sweet-Cordero A; Weissleder R; Jacks T
Cold Spring Harb Symp Quant Biol; 2005; 70():241-50. PubMed ID: 16869760
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
15. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
16. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
Rossi G; Graziano P; Leone A; Migaldi M; Califano R
Semin Diagn Pathol; 2013 Nov; 30(4):298-312. PubMed ID: 24342286
[TBL] [Abstract][Full Text] [Related]
17. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T
Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371
[TBL] [Abstract][Full Text] [Related]
18. New discoveries in lung cancer highlighted at conference.
Printz C
Cancer; 2014 Jun; 120(11):1598-9. PubMed ID: 24844819
[No Abstract] [Full Text] [Related]
19. Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.
Salgia R
Future Oncol; 2015; 11(3):489-500. PubMed ID: 25675128
[TBL] [Abstract][Full Text] [Related]
20. Novel Strategy for Synchronous Multiple Primary Lung Cancer Displaying Unique Molecular Profiles.
Ye C; Wang J; Li W; Chai Y
Ann Thorac Surg; 2016 Feb; 101(2):e45-7. PubMed ID: 26777970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
